hope the Mark. so. way on everyone you, Thank vaccinated, well I this or to and being finds healthy
update progress the top employees keeping first while continue Lantheus During today. successfully we of the I and execute quarter, priority, our operational a against our to you safety on pleased to and financial am strategies,
acquisition As year the am of we of one mark our our approach accomplished. has proud of what Progenics, team I
well may is we achieve invest able recall, for to a savings. cannot to business, the milestones announcing to our more The identified oversee fully excited execution creating over-achieving company. be we targeted advanced are have future significantly integration goals. against on I after and what established that been we while transaction, these the the strategic is in the run effort this rate financial team and dedicated You about
that want reporting this I to your later, to our While a detail Bob will bring change begins provide in segments more attention quarter. with
grouping Going to three international segment. segment, and reporting segments Under our forward, changing into single will we that from we categories. are a reporting be single reported US our revenue
category, DEFINITY. strategic portfolio second with In product I and I the be my this current discussing the Xenon. with following and precision first to our new with I'll structure format. comments consistent the The partnerships and aligns better strategy other. to radiopharmaceutical TechneLite would products, diagnostics, will be DEFINITY, pipeline. start diagnostics, corporate is is precision is first oncology, This and the and third our
see in began vaccines and infections we steadily albeit engaged volume February, broader of see been programs, Throughout will the related segments to December to line Starting continue as If while hospitalizations. virtual to in-person of administering noted technology, availability training that, in direct results with more regions November are in recovery, return DEFINITY we believe that increasing non-urgent becoming has regions customers October procedures to in in promotional in pre-COVID-XX professionals we those our were including echocardiography restricted. with early With that COVID-XX we the XXXX, and decline utilization volumes. healthcare pandemic, late population, digital the and to receiving did through country. And quarter with echocardiography access during care. of we've comfortable you recall, believe our and the in resurgence regional fourth expectations, we hospitals experienced geographic differences across
programs conducted In of virtual we've past in a record year. number the fact,
continues, virtual professionals engagement now allowing sales are visits in-person for hospitals areas. some While in our
the are going engagement last digital of are importantly, While more the year market full approach forms opportunity and by geographically different in-person echocardiography promotional dependent our activities highly over the gained still with will limited, Experience mix engage the and forward. trend we the with our in-person. encouraged of inform customers to to
specialty are to and will drive dynamics levels complemented for believe the XXXX balance utilization of revenue the DEFINITY echocardiography investments beyond. echocardiography committed and these normalized We to and growth return by a
facility manufacturing on Finally, remains project DEFINITY, track. regarding our in-house
or New FDA year-end. later We action Drug year, expect Supplemental an sNDA this to by date submit anticipated the with Application
quarter, batches saleable we commercially that DEFINITY successfully of be first During will approval. the FDA upon manufactured
in performed back see levels. build Turning to pre-COVID-XX TechneLite, the to demand QX, toward product we and continue well
to did quarter. recent posted business about the magnitude sales not same While on million generator fourth basis, $X.X of revenues a quarter repeat the ANSTO, of opportunistic included XXXX first sequential the flat the in to which
levels, we logistics patterns support will will hopeful logistics inbound complex, to which return more Moly, our supply Molybdenum-XX or that remain international need normal are international for transportation to minimize delivery. for flight Moly While custom
utilization however, concerns. be result to procedures respiratory continues COVID-XX in-hospital Our of impacted negatively a limited Xenon inhalation as business, by of transmission
PyL March, product continue presented one, said transmission to products tumor previously, be with the trial AZEDRA when possible undergoing patient candidates, is trial, and of reduction impacted, patients paraganglioma hyper and data our now the our beginning tumors infected based and were we've aerosol based Meeting, marker by Phase markers discuss on be or give to aerosol protocols in I AZEDRA. who advanced updated studies, may COVID-XX precautionary may tumor AZEDRA, of from update PPGL. a maintain AZEDRA In will In that Society's Xenon X with in XXXX biochemical an pheochromocytoma As while the procedures. radiopharmaceutical Switching we of following, Endocrine pivotal at XXXX. we hospitals XXXX, to majority announced prevent anticipate oncology Endo Annual demonstrated which secreted
to overall tumors. significantly the evaluate both the to important with and clinical and primary correlated reinforcing secondary biomarker benefit life-threatening of relevance endpoint responses response addition, tumor therapeutic and the response biochemical this in with utility the of In study, these the therapy AZEDRA underscoring in marker patients
option the As first PPGL. FDA-approved treatment for only and patients reminder, or AZEDRA advanced a is metastatic with
the new disease During marketing among the and awareness options physicians. we quarter, introduced increase treatment initiatives referring to of
We Somerset patients. increased product new to centers the of education facilitate medical manufacturing at plan for our affairs facility. of ongoing supply, also expand ensure treatment a also peer-to-peer option adequate we excellence this availability To have developed and to staff working with
well for We are future our to redundancy provide of as also manufacturing, manufacturing constructing increased AZEDRA iodine-based capacity as overall additional suite an products.
will suite, to of moving will and in activities the we obtain we believe adequate qualification anticipate the the complete approval during While of that forward. some and the it AZEDRA for these time capacity ensuring FDA result the balance increased some take of demand for manufacturing year
reviewed style prostate product candidates discuss to the PSMA antigen our will in the pipeline, agent with metastatic portfolio and cancer is a PyL locally or prostate PyL. highlighted accepted advanced an in is visualize enables imaging action date tissue I our application product prostate-specific to the targeted with The NDA now for candidate our soft PyL benefit PET cancer. both new and PyL cancer. prostate XX, the Turning recurrent we XXXX. or published with patients clinicians results the data beginning role signed PyL. metastases and clinical Phase May here, drug announced the transforming for membrane FDA to of The both has lead men bone and priority We of play in important in with III in cancer. these to Cancer PyL an the II/III published the high have were PyL's pivotal believe of March, potential management Research. the Journal studies prostate Journal of the Clinical that CONDOR and and results metastatic risk been demonstrate publication In OSPREY or for trial of Urology, recurrent of Phase results
these our pleased this later published date activities. studies our preparation action commercial busy month, PDUFA are we're in prestigious journals. very with and were launch potential We With
talent significant and medical, quality several we have throughout our in our last department our including facilitate of support up organization, months, successful technical medical, a We've scaling the supply efforts to PyL. launch. added product Over on manufacturing capabilities help our chain, and commercial, commercial, focused
been to sales front, strong with enhance medicine with backgrounds to and our commercial nuclear urology the pleased we've ability On effort. recruit our in professionals
leaders key anticipated the our in and that launch markets commercial against plan senior as liaisons place are our Our science are sales medical in matches people hiring timing.
entire Denes, are supporting and medical two Iryna April, Dr. For experience in a have announced radiology clinical PyL Lantheus early teams. we board-certified and team, diagnostics, Dr. both board-certified come industry, in both of practice Bela Teslenko. both them Medical to talents, urologist the and extensive Teslenko, our Dr. and Dr. and in top-tier Denes with we addition the thrilled
Our we timeline supports launching soon as receive FDA as PyL approval.
This We approval manufacturing the our or the the Medicare or hospital year. our product activation to outpatient Services for PMF availability the with Medicaid the of end setting. CMS, Medicare timing facility in pass-through and are expected partners preparedness coverage PET on application for site aligns by with working nationwide Center with and of ensure
for in by payers End the organizations cancer, advocacy We'll with PSMA continues. our PET outreach optimize and We patient are to Foundation working of is notably, well The Cancer, as appropriate Most build with as with prostate awareness of initial clinicians. Prostate a patients imaging engaging number such critical for The insurance. adoption and groups of veterans also the as work PyL ZERO, Prostate our also Cancer commercial of reimbursement voice key groups. includes with of
We interest agent. seen the novel we healthcare from are communities of greatly this encouraged imaging by have the patient in recognition and
our to trial. this across patient avid II am treatment enrollment is progressing trial. trial Patient as US PSMA-targeted and the is target metastatic candidate in enzalutamide the patients for designed Phase combination pleased we with milestones now In alone we progressing have planned chemotherapy-naive ARROW safety XXXX, efficacy sites on mCRPC. I XXXX, enzalutamide XX October as ARROW or that resumed active abiraterone. in who have to enrollment prostate Canada our and The well. product is cancer to iodine-XXX in clinical of with PSMA enrollment patient Moving of radiotherapy report with are and time and I-XXX for progressed XXXX our the mCRPC, compared evaluate to on castrate-resistant we
In tumor-associated partnerships or Noria this this for tumors, and a innovative with Now expressed for fibroblast agent a of to discuss diagnosis is of year, inform this stronger in unmet believed also impact as and types. our over portfolio FAP Lantheus monitor the and NT micro colon, breast, and the multiple potential development in commercialize agent. medical acquired and activation our agreement completion need to offering the business. rights Therapeutics. the I the targeting response. tumor the potential has included in response rights are be fibroblast, option of therapy address pharmaceutical which staging treatment therapeutic worldwide of NTI-XXXX, oncology modulate use protein Noria, has having clinical will to from exclusive strategic to well broad programs. precision academics and target cancer, imaging study, such in research our the we pancreatic to potential pharmaceutical broad FAP the companies which March, NTI-XXXX start management implications tumor believe across late to for later will will by focus an guide be will industry, dense of as develop, integrated progress biomarkers in with Phase applicability manufacture selection to and Under into and immune centers for X part imaging Already NTI-XXXX others a significant oncology. biomarker and target environment, lung patient progression PET to to we tumor Upon as academic specifically acquire Lantheus' to drug FAP, as oncology and
a We the Xerostomia, production and announced side xerostomia. strategic last example follow find, saliva microbubble including effect and which dental it agent, In innovative it and week or collaboration, AHNs permanent for cutting-edge ionizing variety lack a a partnership can common are mouth, of fight early chemotherapy cancer. radiation non-viral will proposed begins, commitment dry cancer. Health radiotherapy diseases. transfer treatment its causes, development. microbubble This oncology issues. that certain head solution of and ultrasound-assisted is radiation-induced this technology enthusiastic in development of of of of also for and franchise, all a neck Allegheny leading xerostomia, to It is has used imaging about suffer gene to patients a cancer treat biomarker our realizing while to which oral is Lantheus' with another a we condition. use Network cause severe xerostomia from Once Thousands advancing is
in it's to progress to development this program. innovative efforts are We AHN excited support
potential Europe, for in to enable software approval. researchers used individual interpretation APROMISE and and in intelligence-based Mark whole a body in with clearance quantify conjunction aPROMISE. locate, announced is give yesterday approval an medical Finally, device Mark PET-CT. CE is professionals we PSMA that disease a and aPROMISE healthcare to past CE milestone in can US the we artificial reader received detect,
Our US to and and I to the the and update on community. in goal the prostate approval cancer programs we portfolio bring turn for to commercial treating the key to offerings aPROMISE this that, over my of call seek is With conclude Bob. Bob? will strategic to add
